Skip to main content
SpringerLink
Log in

Lenalidomide

  • Chapter
  • First Online:
Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 201))

Abstract

Lenalidomide is an immunomodulatory drug (IMiD), which is well established and approved in the treatment of multiple myeloma (MM) and 5q-myelodysplastic syndrome (MDS). The mode of action includes immune modulation, anti-angiogenetic, anti-inflammatory, and anti-proliferative effects. Development of lenalidomide initiated a profound shift in therapeutic approaches especially toward MM. This chapter will discuss the mode of action of lenalidomide as well as its clinical applications. Important clinical phase II and III data of lenalidomide are presented. Currently, lenalidomide is not only investigated in MM and MDS, but also in malignant lymphomas and other entities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Attal M et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782–1791

    Article  CAS  PubMed  Google Scholar 

  • Badoux XC et al (2011) Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489–3498

    Article  CAS  PubMed  Google Scholar 

  • Chanan-Khan A et al (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24(34):5343–5349

    Article  CAS  PubMed  Google Scholar 

  • Chang DH et al (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108(2):618–621

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cives M et al (2012) Lenalidomide in multiple myeloma: current experimental and clinical data. Eur J Haematol 88(4):279–291

    Article  CAS  PubMed  Google Scholar 

  • Corral LG et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386

    CAS  PubMed  Google Scholar 

  • Dahut WL et al (2009) Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 49(6):650–660

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Davies FE et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1):210–216

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123–2132

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11):2147–2152

    Article  CAS  PubMed  Google Scholar 

  • Dredge K et al (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1–2):56–63

    Article  CAS  PubMed  Google Scholar 

  • Ferrajoli A et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291–5297

    Article  CAS  PubMed  Google Scholar 

  • Galustian C et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58(7):1033–1045

    Article  CAS  PubMed  Google Scholar 

  • Gandhi AK et al (2010) Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 10(2):155–167

    Article  CAS  PubMed  Google Scholar 

  • Gupta D et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950–1961

    Article  CAS  PubMed  Google Scholar 

  • Habermann TM et al (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145(3):344–349

    Article  CAS  PubMed  Google Scholar 

  • Heise C et al (2010) Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther 10(10):1663–1672

    Article  CAS  PubMed  Google Scholar 

  • Hsu AK et al (2011) The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 117(5):1605–1613

    Article  CAS  PubMed  Google Scholar 

  • Kotla V et al (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36

    Article  PubMed Central  PubMed  Google Scholar 

  • Larocca A et al (2012) Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Future Oncol 8(10):1223–1238

    Article  CAS  PubMed  Google Scholar 

  • List A et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352(6):549–557

    Article  CAS  PubMed  Google Scholar 

  • McCarthy PL et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770–1781

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mitsiades CS, Mitsiades N (2004) CC-5013 (Celgene). Curr Opin Investig Drugs 5(6):635–647

    CAS  PubMed  Google Scholar 

  • Mitsiades N et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12):4525–4530

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A et al (2010) Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 28(5):800–807

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A et al (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366(19):1759–1769

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Bringhen S, Rajkumar V, Lupparelli G, Usmani SZ, Waage A et al (2013) Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): meta-analysis of 6,383 individual patient data (IPD). J Clin Oncol 31(suppl; abstr 8517)

    Google Scholar 

  • Quach H et al (2012) Lenalidomide in multiple myeloma: current status and future potential. Am J Hematol 87(12):1089–1095

    Article  CAS  PubMed  Google Scholar 

  • Rajkumar SV et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29–37

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ramsay AG et al (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118(7):2427–2437

    CAS  PubMed Central  PubMed  Google Scholar 

  • Raza A et al (2008) Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111(1):86–93

    Article  CAS  PubMed  Google Scholar 

  • Richardson PG et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063–3067

    Article  CAS  PubMed  Google Scholar 

  • Richardson PG et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679–686

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Saloura V, Grivas PD (2010) Lenalidomide: a synthetic compound with an evolving role in cancer management. Hematology 15(5):318–331

    Article  CAS  PubMed  Google Scholar 

  • Sanborn SL et al (2009) Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs 27(5):453–460

    Article  CAS  PubMed  Google Scholar 

  • Sher T et al (2010) Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 51(1):85–88

    Article  CAS  PubMed  Google Scholar 

  • Wang L et al (2013) Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials. Leuk Lymphoma

    Google Scholar 

  • Wang M et al (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716–723

    Article  PubMed  Google Scholar 

  • Wang M et al (2013a) Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902–1909

    Article  CAS  PubMed  Google Scholar 

  • Wang M et al (2013b) Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood

    Google Scholar 

  • Weber DM et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133–2142

    Article  CAS  PubMed  Google Scholar 

  • Wiernik PH et al (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 26(30):4952–4957

    Article  PubMed  Google Scholar 

  • Wu L et al (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14(14):4650–4657

    Article  CAS  PubMed  Google Scholar 

  • Xu Y et al (2009) Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114(2):338–345

    Article  CAS  PubMed  Google Scholar 

  • Zeldis JB et al (2011) A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann NY Acad Sci 1222:76–82

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Hematology and Immunology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 10, 72076, Tuebingen, Germany

    Katja Weisel & Lothar Kanz

Authors
  1. Katja Weisel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lothar Kanz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katja Weisel .

Editor information

Editors and Affiliations

  1. Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Weisel, K., Kanz, L. (2014). Lenalidomide. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54490-3_21

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54489-7

  • Online ISBN: 978-3-642-54490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation